Regulations.gov document
Migraine: Developing Drugs for Acute Treatment; Guidance for Industry; Availability
Notice · FDA-2022-D-1729 · posted Aug 15, 2022
Key facts
| Document ID | FDA-2022-D-1729-0003 |
|---|---|
| Title | Migraine: Developing Drugs for Acute Treatment; Guidance for Industry; Availability |
| Document type | Notice |
| Subtype | Notice of Availability |
| Agency | FDA |
| Docket | FDA-2022-D-1729 |
| Posted | Aug 15, 2022 |
| Federal Register citation | 83 FR 7056 |
| FR document number | 2018-03224 |
| Comment period opens | Aug 15, 2022 |
| Effective date | Feb 16, 2018 |
At a glance
- 1–9 Pages
- 1–9 Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: